Stockscreener 앱 받기
8.40
2.21%
-0.19
시간 외 거래:
8.39
-0.010
-0.12%
전일 마감가:
$8.59
열려 있는:
$8.57
하루 거래량:
36,060
Relative Volume:
0.95
시가총액:
$48.57M
수익:
$43.77M
순이익/손실:
$-35.04M
주가수익비율:
-2.5829
EPS:
-3.2521
순현금흐름:
$-5.51M
1주 성능:
-3.34%
1개월 성능:
+17.62%
6개월 성능:
-24.05%
1년 성능:
-15.73%
1일 변동 폭
$8.33
$8.74
1주일 범위
$8.3185
$8.899
52주 변동 폭
$6.4652
$16.52
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
8.40 | 49.67M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Levels Update: Is Xilio Therapeutics Inc attractive for institutional investorsRate Hike & Risk Managed Investment Signals - baoquankhu1.vn
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - ADVFN
Certain Pre-Funded Warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Common Stock of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Energy Moves: What is the long term forecast for Xilio Therapeutics Inc stockEarnings Beat & Reliable Breakout Forecasts - baoquankhu1.vn
Surprises Report: How cyclical is Xilio Therapeutics Incs revenue streamQuarterly Investment Review & Real-Time Stock Entry Alerts - baoquankhu1.vn
XLO Should I Buy - Intellectia AI
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Xilio Therapeutics, Inc. (XLO) stock price, news, quote and history - Yahoo Finance UK
Xilio Therapeutics Announces Inducement Grants - National Today
Xilio Therapeutics Grants Inducement Shares Under Nasdaq Rule - National Today
XLO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Xilio Therapeutics (XLO) Raised to Buy: How Will This Impact the Shares? - Bitget
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Update Report: Does Xilio Therapeutics Inc have high return on assets2026 Rallies & Risk Controlled Stock Alerts - baoquankhu1.vn
Retail Trends: Can Xilio Therapeutics Inc deliver alphaMarket Sentiment Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
[Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan
Shannon James Samuel, Xilio Therapeutics director, buys $43,949 in shares - Investing.com
Shannon James Samuel, Xilio Therapeutics director, buys $43,949 in shares By Investing.com - Investing.com India
Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy - MarketBeat
Retail Trends: Can Xilio Therapeutics Inc expand into new marketsWeekly Stock Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Market Catalysts: How much upside does Xilio Therapeutics Inc have2026 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Xilio Therapeutics Extends Cash Runway Through 2027 and Advances Masked Immuno-Oncology Pipeline, Including XTX501 and Multi-Specific T Cell Engagers 123 - Minichart
Xilio plans mid-2026 IND filing for cancer therapy XTX501 By Investing.com - Investing.com Australia
Xilio Therapeutics: Advancing Masked Immuno-Oncology Therapies for Improved Cancer Outcomes - Minichart
Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xilio plans mid-2026 IND filing for cancer therapy XTX501 - Investing.com
Xilio Therapeutics 2025 10-K: Revenue $43.8M, EPS (loss) $0.00 - TradingView
Xilio Therapeutics (XLO) outlines masked immuno-oncology pipeline and big pharma deals - Stock Titan
XLO: Collaboration revenue surged and cash runway extended as pipeline advanced toward key milestones - TradingView
Xilio (NASDAQ: XLO) boosts 2025 revenue and cash runway into 2027 - Stock Titan
BRIEF-Xilio Therapeutics Q4 Net Income USD 10.36 Million - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Xilio Therapeutics Inc Share Price USD0.0001 - Hargreaves Lansdown
If You Invested $1,000 in Xilio Therapeutics, Inc. (XLO) - Stock Titan
Volume Summary: Can Xilio Therapeutics Inc deliver alphaWeekly Stock Summary & Daily Entry Point Alerts - baoquankhu1.vn
Trading Recap: What is the long term forecast for Xilio Therapeutics Inc stockGold Moves & Community Consensus Picks - baoquankhu1.vn
Can Xilio Therapeutics Inc sustain earnings growthWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Exit Recap: Will Boyd Gaming Corporation stock benefit from M A2026 EndofMonth & Weekly Return Optimization Plans - baoquankhu1.vn
XLO Forecast, Price Target & Analyst Ratings | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill
Big Picture: Why is Xilio Therapeutics Inc stock going downWeekly Risk Report & Proven Capital Preservation Methods - baoquankhu1.vn
Analysis Recap: Whats the outlook for JB Hunt Transport Services Incs sector2026 Selloffs & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Xilio Therapeutics to present data on masked cancer therapy at AACR - Investing.com Australia
Xilio Therapeutics to present data on masked cancer therapy at AACR By Investing.com - Investing.com South Africa
Xilio Therapeutics to Present Poster on XTX601 at AACR Annual Meeting 2026 - Quiver Quantitative
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program ... - Bluefield Daily Telegraph
Xilio Therapeutics to Present New Preclinical Data for its - GlobeNewswire
Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8%What's Next? - marketbeat.com
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting - Bitget
Inflation Data: Whats the fair value of Xilio Therapeutics Inc stock2026 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):